Bambusa Therapeutics, Inc. (BBTX)
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Bambusa Therapeutics Inc.
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company.
It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases.
The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
US| Name | Shares | % | Source |
|---|---|---|---|
 Salvia Investment GmbH 10% Owner | 4.1M | -- | FORM 4 |
Insiders
- Salvia Investment GmbH10% Owner
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company.
It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases.
The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
US30d Avg
2.20M
60d Avg
2.20M
90d Avg
2.20M